How have PDSB and RXRX total returns compared?

Over the past 5 years, PDSB delivered -45.19% and RXRX delivered -28.56% annualized total return. Past performance doesn't predict future results.

PDS Biotechnology Corporation (PDSB) vs Recursion Pharmaceuticals, Inc. (RXRX)

A side-by-side comparison of PDS Biotechnology Corporation and Recursion Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 2, 2026. Differences are shown without an overall score or investment verdict.

PDSB

PDS Biotechnology Corporation

$41M

$0.73HealthcareDelayed quote: Oct 2, 2026, 3:40 PM EDT

RXRX

Recursion Pharmaceuticals, Inc.

$2.14B

$4.08HealthcareDelayed quote: Oct 2, 2026, 3:40 PM EDT

Total return — PDSB vs RXRX

growth of $100 · dividends reinvested · last 5y

PDSB -86.7% (-33.2%/yr)RXRX -77.4% (-25.7%/yr)RXRX compounded faster over this window

PDSB RXRX

PDSB vs RXRX: by the numbers

•RXRX is the larger company ($2.14B vs $41M market cap).
•Both run net losses; PDSB's is the smaller (0.00% vs -945.92% net margin).

Metrics side by side

Valuation

Metric	PDSB	RXRX
P/S ratio	N/A	39.05
P/B ratio	N/A	2.34

Profitability

Metric	PDSB	RXRX
Gross margin	0.00%	-61.96%
Operating margin	0.00%	-867.87%
Net margin	0.00%	-945.92%
ROE	N/A	-56.71%
ROIC	-3699.99%	-49.78%

Growth (annualized)

Metric	PDSB	RXRX
Revenue CAGR (5Y)	N/A	45.50%
Total return CAGR (5Y)	-45.19%	-28.56%

Frequently asked

How have PDSB and RXRX total returns compared?: Over the past 5 years, PDSB delivered -45.19% and RXRX delivered -28.56% annualized total return. Past performance doesn't predict future results.

Go deeper

Full PDSB analysis Full RXRX analysis Interactive comparison tool

Dig into the metrics

PDS Biotechnology ROE Recursion Pharmaceuticals ROE PDS Biotechnology operating margin Recursion Pharmaceuticals operating margin PDS Biotechnology revenue growth Recursion Pharmaceuticals revenue growth PDS Biotechnology free cash flow Recursion Pharmaceuticals free cash flow

PDS Biotechnology & Recursion Pharmaceuticals appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 2, 2026.